-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Immunotherapy has shown some efficacy in advanced triple-negative breast cancer (TNBC)
.
For example, the phase III clinical study IMpassion130 mainly evaluates atezolizumab combined with albumin-bound paclitaxel (A + nP) vs.
placebo combined with albumin-bound paclitaxel (P+nP) for first-line treatment of untreated, unresectable, locally advanced or metastatic The efficacy and safety of TNBC
Immunotherapy has shown some efficacy in advanced triple-negative breast cancer (TNBC)
IMpassion131 is a global, randomized, double-blind, placebo-controlled phase III trial
.
IMpassion131 is a global, randomized, double-blind, placebo-controlled phase III trial
As of November 15, 2019, the first PFS analysis was conducted
PFS
PFSAs of the final OS analysis on September 4, 2020, among PD-L1 positive patients, the median follow-up time of atezolizumab plus paclitaxel group and placebo plus paclitaxel group was 15.
2 months and 15.
As of the final OS analysis on September 4, 2020, among PD-L1 positive patients, the median follow-up time of atezolizumab plus paclitaxel group and placebo plus paclitaxel group was 15.
OS
OSThe incidence of serious adverse events (AEs) in the two groups was 25% and 18%, respectively; grade 3/4 AEs were 53% and 46%, respectively; grade 5 AEs were 2%
.
The incidence of serious adverse events (AEs) in the two groups was 25% and 18%, respectively; grade 3/4 AEs were 53% and 46%, respectively; grade 5 AEs were 2%
In summary, atezolizumab combined with paclitaxel versus paclitaxel alone cannot improve PFS or OS in patients with unresectable, locally advanced, or metastatic triple-negative breast cancer (TNBC)
Original source:
D.
Miles, J.
D.
Miles, J.
Gligorov, F.
André, et al.
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple- negative breast cancer.
Annals of Oncology, 2021, https://doi.
org/10.
1016/j.
annonc.
2021.
05.
801.
Leave a message here
